New ETF Book by Larry Connors - Click here to read more
CEO Eskil Elmer comments that "This study in 52 healthy subjects is a direct comparison of NeuroVive's injectable cyclosporine product NeuroSTAT(R) with Novartis's product Sandimmune(R) Injection. This is an important milestone in the development of NeuroVive's first pharmaceutical product for clinical use in patients with acute brain damage. Further, if the final analysis of the study is successful it will open the opportunity to develop or outlicense the product NeuroSTAT(R) for existing indications for intravenous cyclosporine A (such as immunosuppression). We expect to make NeuroSTAT(R) available for clinical trials and sales on a named-patient basis."
The study is entitled: "A study to compare the bioavailability and pharmacokinetics of cyclosporine after intravenous administration of NeuroSTAT(R), a Cremophor(R) EL-free lipid emulsion, and Sandimmune(R) Injection (a suspension of cyclosporine in Cremophor(R) EL) in healthy volunteers."
Chairman Greg Batcheller comments "The completion of this trial represents an important step in the development of NeuroSTAT(R). It sets the stage for a next round of financing that will eventually take us into clinical trials in traumatic brain injury patients in Europe and the US."
NeuroSTAT(R) is an intravenous cyclosporine A lipid emulsion which is free from cremophor(R) EL (castor oil) and alcohol. Cremophor(R) EL has been reported to cause hypersensitivity reactions (anaphylaxis) in some patients. The introduction of a cremophor(R) EL-free intravenous cyclosporine A lipid emulsion will provide a safer alternative to patients, similar to the introduction of cremophor-free Paclitaxel (Taxol(R)) and Propofol (Diprivan(R)) products.
NeuroVive Pharmaceutical AB is a Swedish research and development company. NeuroVive's primary mission is to develop drugs which protect nerve cells. The company is currently conducting clinical trials in humans with the product NeuroSTAT(R). In addition to introducing NeuroSTAT(R) as the first cyclophilin-D-inhibiting mitochondrial protectant, NeuroVive is researching and developing variants of cyclophilin-inhibiting cyclosporines and new ways of transporting these drugs across the blood-brain barrier to the central nervous system.
NeuroVive Pharmaceutical AB shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses and offers an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.
Eskil Elmer, MD, PhD CEO and CSO, Neurovive Pharmaceutical AB Biomedical Center, BMC D10 SE-221 84 Lund, Sweden Tel.: +46 (0)733-919601 eskil.elmer@neurovive.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright Copyright Hugin AS 2009. All rights reserved.
SOURCE: NeuroVive Pharmaceutical AB
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
